CERS Key Stats
|Revenue (Quarterly YoY Growth)||27.75%|
|EPS Diluted (TTM)||-0.5908|
|EPS Diluted (Quarterly YoY Growth)|
|Net Income (TTM)||-39.19M|
|Gross Profit Margin (Quarterly)||35.25%|
|Profit Margin (Quarterly)||-194.5%|
|Dividend Yield (TTM)||0.00%|
|Payout Ratio (TTM) Pro||Go Pro|
- Cerus Submits Final Module in the Premarket Approval (PMA) Application Process for INTERCEPT Plasma noodls Dec 4
- CERUS CORP Files SEC form 8-K, Entry into a Material Definitive Agreement Nov 22
- Iceland National Blood Bank Signs INTERCEPT Platelet and Plasma Agreement with Cerus Business Wire Nov 20
- CERUS CORP Financials Nov 7
- Cerus Announces Agreement with Health Canada for Regulatory Submission of the INTERCEPT Blood System for Platelets and Plasma noodls Nov 6
- CERUS CORP Files SEC form 10-Q, Quarterly Report Nov 1
- Cerus and the Swiss Red Cross Renew Commercial Contract with a Five-Year National Purchase Agreement for the INTERCEPT Blood System for Platelets noodls Oct 31
- Cerus Management Discusses Q3 2013 Results - Earnings Call Transcript Seeking Alpha Oct 29
- Cerus Corporation Reports Third Quarter 2013 Results noodls Oct 29
- CERUS CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits Oct 29
CERS Total Returns Comparison
This total returns chart shows the returns to an investor from both price appreciation and dividends (dividends are assumed to be reinvested). Cerus is up 98.41% over the last year vs S&P 500 Total Return up 30.43%, ARCA biopharma down 5.02%, and Merus Labs International up 9.63%.
Fundamental analysis of a business involves analyzing its financial statements and health, its management and competitive advantages. The key financial statements of a company are the income statement, balance sheet and cash flow statement.
Income Statement View Statement
Balance Sheet View Statement
Pro Ratings for CERS
Pro Report PDF for CERS
Download Pro Ratings, Key Stats, Performance Charts, Valuations, and Financials in an easy to print format.Download CERS Pro Report PDF
Pro Strategies Featuring CERS
Did Cerus make it into our Pro Portfolio Strategies?
Start your YCharts Pro membership now to find out.
Cerus Corporation is a biomedical products company, which focuses on commercializing the INTERCEPT Blood System to enhance blood safety.